ACEA (arachidonyl-2-chloroethylamide), the selective cannabinoid CB1 receptor agonist, protects against aspirin-induced gastric ulceration.
The effect of a selective cannabinoid CB1 receptor agonist, ACEA (arachidonyl-2-chloroethylamide) in an aspirin-induced ulcer model was studied in rats. ACEA (1.25-5 mg/kg i.p.) significantly reduced gastric ulcer formation to 24, 21 and 0.6% respectively. These results confirm the cytoprotective effect of CB1 receptor agonists and suggest that the endocannabinoid system might be the target for a novel class of anti-ulcer drugs.
Rutkowska
M
M
Department of Pharmacology, Medical University of Wrocław, 2 Mikulicza-Radeckiego Str., 50-345 Wrocław, Poland. rutkowsk@fa.am.wroc.pl
Fereniec-Gołtbiewska
L
L
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000037:antagonists & inhibitors* / Q000633:toxicity; D000897:Anti-Ulcer Agents; D001095:Arachidonic Acids / Q000494:pharmacology*; D001241:Aspirin / Q000037:antagonists & inhibitors* / Q000633:toxicity; D004305:Dose-Response Relationship, Drug; D005753:Gastric Mucosa / Q000473:pathology; D011899:Ranitidine / Q000627:therapeutic use; D051381:Rats; D043884:Receptor, Cannabinoid, CB1 / Q000819:agonists*; D013276:Stomach Ulcer / Q000139:chemically induced* / Q000473:pathology / Q000517:prevention & control*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000897:Anti-Ulcer Agents; D001095:Arachidonic Acids; D043884:Receptor, Cannabinoid, CB1; C119325:arachidonyl-2-chloroethylamide; D011899:Ranitidine; D001241:Aspirin